Modified radical mastectomy is the standard surgical procedure today in most countries. ‘Lesser surgery’ associated with radiotherapy emerges as an alternative for patients with T1N0 lesions.
The potential risk of occult micrometastases is best predicted by careful axillary staging and possibly by the ER status of the primary tumor.
Additonal risk factors such as tumor size, patient age, menopausal status, and intramammary lymphatic or vascular invasion are less well established and need clarification.
Previous studies showed no significant long-term benefit of adjuvant radiotherapy and at best a marginal increase of lifespan by adjuvant castration in patients subjected to radical surgery.
Various types of adequately intensive adjuvant chemotherapy resulted in a significant increase of relapse-free survival and probably also overall survival 5–6 years after mastectomy in pre- and possibly also postmenopausal N+ patients.
Treatment intensity (full doses) of adjuvant chemotherapy seems to be more critical than treatment duration (CMFx6 is as good as CMFx12).
Adjuvant chemotherapy with drug combinations is generally more effective than single drugs. No combination so far (if adequate doses are given) is clearly superior.
Whether early peri-operative onset of adjuvant chemotherapy or combinations with endocrine measures or cyclic, alternating drug regimens increase effectiveness remains to be shown.
Adjuvant chemotherapy in N- patients, though still experimental, appears rewarding.
The pattern of first relapse has not been significantly altered by the use of adjuvant chemotherapy. Response rate and duration with secondary treatments are consistent with common experience in metastatic disease.
Up to 5–6 years median observation time there is no proof that the risk of second neoplasms is increased by currently used adjuvant chemotherapy regimens.
More and highly critical prospective trials are needed to assess not only effectiveness, but also patient tolerance (cost-benefit ratio) of adjuvant therapies in breast cancer.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Ahmann DL, Payne WS, Scanlon PW, et al. (1978) Adjuvant chemotherapy with l-PAM or FCP with or without radiation after mastectomy for breast cancer. Lancet 1:893
Allen H, Brooks R, Jones SE, et al. (1981) Adjuvant treatment for stage II (node-positive) breast cancer with adriamycin + cyclophosphamide. Adjuvant Therapy of Cancer III. Grune & Stratton, New York, p 453
Baum M (1977) Multimodal therapy for stage II breast cancer. Lancet 2:564
Billingham ME, Mason JW, Bristow MR, et al (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62:865
Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10
Bonadonna G, Valagussa P (to be published) Adjuvant therapy of primary breast cancer. In: Carter SK, Glatstein E, Livingston RB (eds) Principles of cancer treatment
Bonadonna G, Valagussa P, Rossi A, et al. (1978) Are surgical adjuvant trials altering the course of breast cancer? Semin Oncol 5:450
Bonadonna G, Rossi A, Tancini G, et al. (1981) Adjuvant treatment for breast cancer: The Milan Institute experience. Abstract no. 49, Third International Conference on Adjuvant Therapy of Cancer, Tucson
Brinkley D, Haybittle JL (1975) The curability of breast cancer. Lancet 2:95
Brunner KW, Sonntag RW, Alberto P, et al. (1977) Combined chemo- and hormonotherapy in advanced breast cancer. Cancer 39:2923
Bucalossi P, Veronesi U, Pizzocaro G, Zucali R (1977) Risultati della radiotherapia preoperatioria nel carcinoma mammario. Tumori 58:203
Buzdar AU, Blumenschein GR, Hortobagyi GN, Yap HY (1980) Five-year follow-up of FAC-BCG adjuvant therapy of stage II and III breast cancer. Cancer Chemother Pharmacol 5:8
Carey RW, Holland JF, Shehe P, Graham S (1967) Association of cancer of the breast and acute myelocytic leukemia. Cancer 20:1080
Carter SK (1974) The chemical therapy of breast cancer. Semin Oncol 1:131
Casiato DA, Scott JL (1979) Acute leukemia following prolonged cytotoxic agent therapy. Medicine (Baltimore) 58:32
Cooper RG, Holland JF, Glidewell O (1979) Adjuvant chemotherapy for breast cancer. Cancer 44:793
Cutter SJ, Myers MH, Green SB (1975) Trends in survival rates of patients with cancer. N Engl J Med 293:122
Davis HL, Metter GE, Ramirez G, et al. (1979) An adjuvant trial of l-PAM vs. CMF-V following mastectomy for operable breast cancer. Proc Am Soc Clin Oncol 20:358
Denzler O, Senn HJ (to be published) Adjuvante Chemotherapy bei operablem Mamma-Karzinom: Einfluß von Therapieintensität und Rezidivmuster auf die Prognose
Doll R, Muir G, Waterhouse J (1970) Cancer-Incidence in 5 continents. UICC/Springer, Berlin Heidelberg New York
Fisher B (1979) Breast cancer management: Alternatives to mastectomy. N Engl J Med 301:326
Fisher B (1980) Laboratory and clinical research in breast cancer — A personal adventure. Cancer Res 40:3863
Fisher B, Slack NH, Bross IDJ, et al. (1969) Cancer of the breast: Size of neoplasms and prognosis. Cancer 24:1071
Fisher B, Slack NH, Cavanaugh PJ, et al. (1970) Postoperative radiotherapy in the treatment of breast cancer: results of the NSBAP trial. Ann Surg 172:711
Fishcer B, Slack NH, Katrych D, Wolmark N (1975) Ten years of follwo-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140:528
Fisher B, Redmond C, Fisher ER, and NSABP investigators (1980) The contribution of recent NSABP trials of primary breast cancer therapy to an understanding of tumor biology. Cancer 46:1009
Fisher B, Redmond C, Brown A, et al. (1981) Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305:1
Glucksberg H, Vivkin SE, Rasmussen S (1979) Adjuvant chemotherapy for stage II breast cancer: A comparison of CMFVP vs l-PAM. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer, vol II. Grune & Stratton, New York, p 269
Halsted WS (1894) The results of operations for the cure of breast cancer. Johns Hopkins Hospital Report 4:297
Jones SE, Moon T, Davis S, et al. (to be published) Comparative analysis of selected breast cancer trials in relation to the natural history obta base
Jungi WF, Alberto P, Brunner KW, et al. (1981) Short- or long-term chemotherapy for breast cancer? Abstract no. 38, Third International Conference on adjuvant therapy of cancer, Tucson
Kardinal SG, Donegan WL (1980) Second cancers after prolonged adjuvant Thio-Tepa for operable breast cancer. Cancer 45:2042
Ludwig SAKK Breast Cancer Study Group (1981) Ongoing trials I–IV and proposed trial V
Meakin JW, Allt FA, Beale TC, et al. (1977) Ovarian irradiation and prednisone following surgery for carcinoma of the breast. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer. Elsevier, Amsterdam, p 95
Moxley JH, Allegra JC, Henney J, Muggia F (1980) Treatment of primary breast cancer. Summary of the NIH Conseses development conference. JAMA 244:797
Nissen-Meyer R, Kjellgren K, Malmio K, et al. (1978) Surgical adjuvant chemotherapy. Results with one short course of cyclophosphamide after mastectomy for breast cancer. Cancer 41:2088
Rosner F, Grunwald H (1975) Hodgkin's disease and acute leukemia. Report of 8 cases and review of the literature. Am J Med 57:927
Rosner F, Carey RW, Zarcabi MH (1978) Breast cancer and acute leukemia. Report of 24 cases and review of the literature. Am J Hematol 4:151
Rossi A, Tancini G, Marchini S, Bonadonna G (1980) Response to secondary treatment after surgical adjuvant CMF for breast cancer. AACR Absgtract, San Diego
Rossi A, Bonadonna G, Valagussa P, Veronesi V (1981) Multinodal treatment of operable breast cancer: 5-y. Results of the CMF programm. Br Med J 282:1427
Schabel F (1977) Surgical adjuvant chemotherapy of metastatic murine tumors. Cancer 40:558
Senn HJ (1978) Behandlungsfortschritte durch multimodale Therapie beim Mammakarzinom. Schweiz Med Wochenschr 108:1938
Senn HJ, Mayr AC (1979) Adjuvant chemotherapy in breast cancer — Swiss cooperative studies. Cancer Treat Rev [Suppl] 6:79
Senn HJ, Amgwerd R, Jungi WF, et al. (1981) Adjuvant chemo-immunotherapy with LMF+BCG in node-positive and node-negative breast cancer, 5-y. Results of a randomized study. In: Salmon EE, Jones SE (eds) Adjuvant Therapy of Cancer III. Grune and Stratton, New York, p 385
Skipper HE (1978) Adjuvant chemotherapy. Cancer 41:936
Stjernsward J (1974) Decreased survival related to irradiation postoperatively in early operable breast cancer. Lancet 2:1285
stjernsward J (1977) Adjuvant radiotherapy trials in breast cancer. Cancer 39:2846
Tancini G, Bajetta E, Marchini S, et al. (1979) Preliminary 3-year results of 12 vs 6 cycles of surgical adjuvant CMF in premenopausal breast cancer. Cancer Clin Trials 2:285
Tormey D, Holland JF, Weinberg V, et al. (1981) 5-drug vs 3-drug ± MER postoperative chemotherapy for mammary carcinoma. Abstract no. 36, Third International Conference on Adjuvant Therapy of Cancer, Tucson
Valagussa P, Bonadonna G, Veronesi U (1978) Patterns of relapse and survival following radical mastectomy. Analysis of 716 cases. Cancer 41:1170
Van der Linde F (1977) Definition der Bevölkerungsgruppen mit hohem Risiko beim Mammakarzinom. Schweiz Med Wochenschr 107:962
Van Dyck JJ, Falkson G (1971) Extended survival and remission rate in metastatic breast cancer. Cancer 27:300
Veronesi U, Valagussa P (1981) Inefficacy of internal mammary node dissection in breast cancer surgery. Cancer 304:10–15
Veronesi U, Saccozzi R, Del Vecchio M, et al. (1981) Comparing radical mastectomy with quadrantectomy, axillary dissection and radiotherapy in patients with small cancers of the breast. N Engl J Med 305:6
Weiss RB, Henney JE, De Vita VT (1981) Multimodal treatment of primary breast carcinoma, analysis of accomplishments and problem areas. Am J Med 70:844
This article is based on a paper presented in Session II: Symposium on the Current Status of Adjuvant Chemotherapy at the Twelfth International Congress of Chemotherapy, Florence, Italy, 20 July 1981
About this article
Cite this article
Senn, H.J. Current status and indications for adjuvant therapy in breast cancer. Cancer Chemother. Pharmacol. 8, 139–150 (1982). https://doi.org/10.1007/BF00255474
- Breast Cancer
- Adjuvant Chemotherapy
- Adjuvant Therapy
- Menopausal Status
- Radical Mastectomy